Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
- 26 June 2014
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 63 (9) , 977-983
Abstract
Immune checkpoints are a series of inhibitory pathways that are crucial for modulating the intensity and duration of immune response. Among these checkpoints, cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) has been shown to be a key regulator of the early activation of naïve and memory T cells. Immune checkpoint blockade is emerging as one of the most promising therapeutic approaches directed toward the activation of the immune response against tumors. The first of these therapies that has been FDA approved is ipilimumab, a fully human monoclonal antibody that blocks CTLA-4. The in cis effects that CTLA-4 blockade has on T cells have been properly described, but there are still questions to be answered regarding the indirect or in trans effects. One of the alternative cellular populations that may play a role in the outcome of CTLA-4 blockade therapy is myeloid-derived suppressor cells (MDSCs), which have recently been associated with clinical outcome in advanced melanoma. In addition to this, MDSCs have been shown to be decreased in number and functional potential after treatment with ipilimumab. A better clarification of what effects CTLA-4 blockade may have on these cellular populations is likely to provide insights on possible predictive biomarkers for CTLA-4 blockade therapy.Keywords
This publication has 55 references indexed in Scilit:
- CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentationBMC Immunology, 2011
- A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTIONAnnual Review of Immunology, 2006
- Expression of CTLA‐4 by Human MonocytesScandinavian Journal of Immunology, 2002
- Inhibition of IgG1 and IgE Production by Stimulation of the B Cell CTLA-4 ReceptorThe Journal of Immunology, 2000
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- CTLA-4 is a second receptor for the B cell activation antigen B7.Journal of Experimental Medicine, 1991
- CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.Proceedings of the National Academy of Sciences, 1989
- T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.Molecular and Cellular Biology, 1987
- A new member of the immunoglobulin superfamily—CTLA-4Nature, 1987